Literature DB >> 12450301

Management of juvenile idiopathic arthritis.

Sujata Sawhney1.   

Abstract

Juvenile idiopathic arthritis (JIA) is a relatively uncommon disorder in childhood. Expertise however should be the corner stone of care of children with JIA, as early appropriate treatment is mandatory to ensure best possible short and long-term outcome for children with JIA. Therefore comprehensive treatment centers (with multi disciplinary teams) should be based in tertiary level academic centers. This article deals with both specific and generic issues encountered in managing children with JIA.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12450301     DOI： 10.1007/bf02723715

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  29 in total

1.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders.

Authors:  S Sawhney; P Woo; K J Murray
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

2.  Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group.

Authors:  M A van Rossum; T J Fiselier; M J Franssen; A H Zwinderman; R ten Cate; L W van Suijlekom-Smit; W H van Luijk; R M van Soesbergen; N M Wulffraat; J C Oostveen; W Kuis; P F Dijkstra; C F van Ede; B A Dijkmans
Journal:  Arthritis Rheum       Date:  1998-05

Review 3.  Juvenile chronic arthritis.

Authors:  P Woo; L R Wedderburn
Journal:  Lancet       Date:  1998-03-28       Impact factor: 79.321

4.  Preliminary definition of improvement in juvenile arthritis.

Authors:  E H Giannini; N Ruperto; A Ravelli; D J Lovell; D T Felson; A Martini
Journal:  Arthritis Rheum       Date:  1997-07

5.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors:  D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal:  N Engl J Med       Date:  2000-03-16       Impact factor: 91.245

6.  Juvenile chronic arthritis into adulthood: a long-term follow-up study.

Authors:  M Zak; F K Pedersen
Journal:  Rheumatology (Oxford)       Date:  2000-02       Impact factor: 7.580

Review 7.  Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.

Authors:  Roy Fleischmann; Imran Iqbal; Pallavi Nandeshwar; Andres Quiceno
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Current treatment of juvenile rheumatoid arthritis.

Authors:  Norman T Ilowite
Journal:  Pediatrics       Date:  2002-01       Impact factor: 7.124

9.  Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis.

Authors:  A H Weiss; C A Wallace; D D Sherry
Journal:  J Pediatr       Date:  1998-08       Impact factor: 4.406

Review 10.  Prognostic factors in juvenile idiopathic arthritis.

Authors:  A M Prieur; G Chèdeville
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.686
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.